Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 33.98 CNY 0.59% Market Closed
Market Cap: 26.2B CNY

EV/EBITDA
Enterprise Value to EBITDA

32.2
Current
30.4
Median
12.8
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
32.2
=
Enterprise Value
22.4B CNY
/
EBITDA
695m CNY

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
12.4
2-Years Forward
EV/EBITDA
10.8
3-Years Forward
EV/EBITDA
N/A